This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 1992 Apr;10(4):513-4.

doi: 10.1200/JCO.1992.10.4.513.

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

M Markman, W Hoskins

PMID: 1548513
DOI: 10.1200/JCO.1992.10.4.513

Editorial

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

M Markman et al. J Clin Oncol. 1992 Apr.

. 1992 Apr;10(4):513-4.

doi: 10.1200/JCO.1992.10.4.513.

Authors

M Markman, W Hoskins

PMID: 1548513
DOI: 10.1200/JCO.1992.10.4.513

No abstract available

PubMed Disclaimer

Comment on

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.
Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E. Jodrell DI, et al. J Clin Oncol. 1992 Apr;10(4):520-8. doi: 10.1200/JCO.1992.10.4.520. J Clin Oncol. 1992. PMID: 1548516 Clinical Trial.

Similar articles

Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.
Markman M. Markman M. Semin Oncol. 1994 Apr;21(2 Suppl 2):17-9; quiz 20, 58. Semin Oncol. 1994. PMID: 8202717 Review.
Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
Markman M, Reichman B, Hakes T, Rubin S, Lewis JL Jr, Jones W, Barakat R, Curtin J, Almadrones L, Hoskins W. Markman M, et al. Gynecol Oncol. 1993 Jul;50(1):100-4. doi: 10.1006/gyno.1993.1171. Gynecol Oncol. 1993. PMID: 8349150
Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A, Tambaro R, Greggi S, Prato R, Di Maio M, Esposito G, Scala F, Barletta E, Losito S, De Vivo R, Iaffaioli VR, Pignata S. Ottaiano A, et al. Anticancer Res. 2003 Jul-Aug;23(4):3465-8. Anticancer Res. 2003. PMID: 12926091 Clinical Trial.
Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Markman M, et al. Gynecol Oncol. 1997 Jun;65(3):434-6. doi: 10.1006/gyno.1997.4708. Gynecol Oncol. 1997. PMID: 9190971
Role of carboplatin in ovarian cancer. Current results and thoughts for the future.
Ozols RF. Ozols RF. Acta Obstet Gynecol Scand Suppl. 1992;155:75-7. Acta Obstet Gynecol Scand Suppl. 1992. PMID: 1502894 Review.

See all similar articles

Cited by

Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies.
Sood AK, Sorosky JI, Squatrito RC, Skilling JS, Anderson B, Buller RE. Sood AK, et al. Neoplasia. 1999 Jun;1(2):118-22. doi: 10.1038/sj.neo.7900019. Neoplasia. 1999. PMID: 10933045 Free PMC article.
A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer.
Guppy AE, Nelstrop AE, Foster T, Agarwal R, Seckl MJ, Rustin GJ. Guppy AE, et al. Br J Cancer. 2004 Feb 23;90(4):810-4. doi: 10.1038/sj.bjc.6601618. Br J Cancer. 2004. PMID: 14970858 Free PMC article. Clinical Trial.
Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.
Lee CR, Faulds D. Lee CR, et al. Drugs. 1995 Jun;49(6):932-53. doi: 10.2165/00003495-199549060-00007. Drugs. 1995. PMID: 7641606 Review.
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.
Harrison ML, Gore ME, Spriggs D, Kaye S, Iasonos A, Hensley M, Aghajanian C, Venkatraman E, Sabbatini P. Harrison ML, et al. Gynecol Oncol. 2007 Sep;106(3):469-75. doi: 10.1016/j.ygyno.2007.05.008. Epub 2007 Jul 5. Gynecol Oncol. 2007. PMID: 17614127 Free PMC article.
Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer.
du Bois A, Meerpohl HG, Madjar H, Spinner D, Dall P, Pfisterer J, Bauknecht T. du Bois A, et al. J Cancer Res Clin Oncol. 1994;120(3):173-8. doi: 10.1007/BF01202198. J Cancer Res Clin Oncol. 1994. PMID: 8263015 Free PMC article. Clinical Trial.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information